BROOKLYN IMMUNOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 2.02 Results of Operations and Financial Condition.

On April 15, 2022, Brooklyn ImmunoTherapeutics, Inc. ("we," "us," "our" or the "Company") issued a press release announcing its financial results for the three-month period and fiscal year ended December 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.

Item 7.01 Regulation FD Disclosure.

The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.

The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit                                 Description
 Number
  99.1     Press release of Brooklyn ImmunoTherapeutics, Inc. dated April 15,
           2022 announcing the Company's financial results for the three months
           and year ended December 21, 2021.
  104      Cover Page Interactive Data File (embedded within the Inline XBRL
           document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses